Two of Bambusa’s bispecific antibody candidates for immunological and inflammatory disorders are set to enter the clinic in ...

Innovative Bispecific Antibody Therapies in Cancer Treatment Emerge as Patent Filings SurgeDublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody & Cancer Patent Landscape Analysis" report ...

在2024年斩获1500万美元种子轮融资的基础上，Bambusa Therapeutics日前再获9000万美元A轮资金加持，持续深化其在免疫-炎症领域双特异性抗体疗法的创新布局。 本轮本轮融资由RA Capital ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Researchers from Tianjin University have published data regarding development and preclinical characterization of a new anti-PD-L1/CD40 bispecific antibody (BsAb), BA-4415, designed to activate CD40 ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...

Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...